Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report

Area of Science:

• Oncology
• Immunotherapy
• Clinical Research

Background:

• Metastatic nonsquamous non-small-cell lung cancer (mNSCLC) presents treatment challenges.
• Chemotherapy-immunotherapy (CT-IT) is an emerging treatment modality.
• Real-world data is crucial for understanding treatment efficacy and safety.

Purpose of the Study:

• To evaluate the clinical outcomes of CT-IT in a real-world mNSCLC patient cohort.
• To identify and quantify toxicities associated with CT-IT treatment.
• To explore potential correlations between adverse events and treatment effectiveness.

Main Methods:

• Retrospective analysis of clinical data from 26 mNSCLC patients treated with CT-IT.
• Data collected from January 2020 to January 2021.
• Assessment of progression-free survival and immune-related adverse events.

Main Results:

• Median progression-free survival was 9.5 months.
• Thyroid dysfunction (ThD) was the most frequent immune-related adverse event, occurring in 30.7% of patients.
• A higher incidence of ThD was observed compared to existing literature.

Conclusions:

• CT-IT demonstrates a notable progression-free survival in mNSCLC patients.
• The observed high rate of thyroid dysfunction warrants further investigation.
• A potential correlation between thyroid dysfunction and clinical outcomes in mNSCLC patients treated with CT-IT may exist.